no more compounding glp 1 drugs GLP-1 Compounding: When Innovation May Mean Liability Hims & Hers stock falls

J Pharm Technol

Tirzepatide is also contraindicated in individuals with a history of multiple endocrine neoplasia syndrome Type-2 (MEN 2)

A 2024 scoping review by Karacabeyli and Lacaille found GLP-1 medications inhibit the NF-kB pathway one of the bodys master inflammation switches in RA and psoriasis cell models, even before weight changes

We acknowledge that there were some differences in the comparison between GLP-1RAs and other glucose-lowering agents, particularly concerning HbA 1c levels, the use of insulin and the use of SGLT2 inhibitors, which may have influenced the results

This framework explains why some patients see dramatic improvements while others see modest changes

S.DennisB